BIO-TECHNE Corp
Financial highlights
| Metric | FY 06/30/26 | FY 06/30/25 | FY 06/30/24 | FY 06/30/23 | FY 06/30/22 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.2B | $1.2B | $1.2B | $1.1B | $1.1B |
| Cost of revenue | $416.0M | $429.4M | $389.3M | $366.9M | $349.1M |
| Gross profit | $799.1M | $790.3M | $769.7M | $769.8M | $756.5M |
| Selling, general & administrative | $452.4M | $588.5M | $466.4M | $378.4M | $372.8M |
| Research and development | $94.8M | $99.5M | $96.7M | $92.5M | $87.1M |
| Operating expenses | $547.2M | $688.0M | $563.0M | $470.9M | $459.9M |
| Operating income | $251.9M | $102.3M | $206.7M | $298.9M | $296.6M |
| Interest expense | $9.6M | $8.5M | $15.7M | $11.2M | $11.3M |
| Pretax income | $240.7M | $98.5M | $185.7M | $338.7M | $301.4M |
| Income tax expense | $58.8M | $25.1M | $17.6M | $53.2M | $38.3M |
| Net income | $181.9M | $73.4M | $168.1M | $285.3M | $272.1M |
| Balance Sheet | |||||
| Cash and equivalents | $264.7M | $162.2M | $151.8M | $180.6M | $172.6M |
| Current assets | $744.4M | $608.3M | $617.4M | $621.5M | $605.6M |
| Total assets | $2.6B | $2.6B | $2.7B | $2.6B | $2.3B |
| Current liabilities | $163.7M | $175.8M | $159.4M | $128.5M | $176.0M |
| Stockholders' equity | $2.1B | $1.9B | $2.1B | $2.0B | $1.7B |
| Cash Flow Statement | |||||
| Cash from operations | $292.1M | $287.6M | $299.0M | $254.4M | $325.3M |
| Depreciation and amortization | $97.4M | $109.9M | $111.7M | $107.2M | $101.1M |
| Stock-based compensation | $41.4M | $40.8M | $38.0M | $39.2M | $42.2M |
| Capital expenditure | $28.9M | $31.0M | $62.9M | $38.2M | $44.9M |
| Free cash flow | $263.2M | $256.6M | $236.1M | $216.1M | $280.4M |
| Dividends paid | $49.9M | $50.4M | $50.4M | $50.3M | $50.2M |
| Share repurchases | $41.7M | $275.7M | $80.0M | $19.6M | $160.9M |
| Impairments | — | $0 | $0 | $0 | $8.3M |
Shares outstanding 156.6M · Free float 98.7%
Annual filing data through FY ended June 30, 2026; float as of August 14, 2026.